VitaSpring Biomedical Reports Net Loss of $75,844 with No Revenue for Q2 2026

VitaSpring Biomedical Co., Ltd. reported its financial results for the three months ending April 30, 2026, revealing a net loss of $75,844, a slight improvement from a net loss of $80,541 during the same period in 2025. The company did not generate any revenue in either period, maintaining a consistent lack of active revenue-generating operations. Operating expenses increased to $75,844 from $69,147 year-over-year, primarily driven by selling, general, and administrative expenses. The company’s accumulated deficit rose to $5,772,715 as of April 30, 2026, compared to $5,696,871 at the end of the previous fiscal period.

Total assets decreased to $11,432,000 from $14,676,000, largely due to a reduction in long-term assets, which fell from $4,149,000 to $1,660,000. Current liabilities remained relatively stable, increasing slightly from $4,445,244 to $4,517,844. The company’s cash position improved, with cash on hand rising to $8,167 from $2,084. Despite this increase, the company reported a working capital deficit of $4,508,072, raising concerns about its ability to continue as a going concern without additional financing.

VitaSpring has not made any significant strategic developments such as acquisitions or product launches during this reporting period. The company continues to focus on its core mission of developing stem cell applications in regenerative medicine, but it has not yet established a revenue stream from these initiatives. The company’s operational metrics indicate that it has maintained a consistent number of shares outstanding at 207,030,030, with no new equity financing reported during the quarter.

Management has indicated that the company plans to seek additional capital through equity financing and strategic partnerships to fund its operations and meet obligations. However, there is no assurance that such financing will be available on acceptable terms. The company’s reliance on advances from related parties, which totaled $1,052,351 as of April 30, 2026, underscores its precarious financial position. The accounts payable to a related party, amounting to $2,411,000, is subject to a deferral agreement, which may provide temporary relief but does not resolve the underlying liquidity issues.

Looking ahead, VitaSpring's management acknowledges the substantial doubt about the company's ability to continue as a going concern within the next year. The company’s financial statements reflect ongoing challenges, including a lack of revenue generation and significant liabilities. The management's strategy to address these challenges will be critical as the company navigates its financial landscape in the coming months.